Pulmonary hypertension screening: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Anmol Pitliya (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators, Widget editors
9,217 edits
Anmol Pitliya (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators, Widget editors
9,217 edits
No edit summary
Line 4: Line 4:
==Overview==
==Overview==


Patients with a known [[BMPR2]] [[mutation]], [[scleroderma]], and [[portal hypertension]] undergoing evaluation for [[liver transplantation]] should receive periodic screening for pulmonary hypertension (PH) through a thorough assessment of the presence of symptoms, physical examination, [[chest X ray]], [[electrocardiography]], and [[echocardiogram]].  Additional investigation with [[right heart catheterization]] should be performed if screening is suggestive of the presence of PH.<ref>ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension</ref>
Patients with a known [[BMPR2]] [[mutation]], [[scleroderma]], and [[portal hypertension]] undergoing evaluation for [[liver transplantation]] should receive periodic screening for pulmonary hypertension (PH) through a thorough assessment of the presence of symptoms, physical examination, [[chest X ray]], [[electrocardiography]], and [[echocardiogram]].  Additional investigation with [[right heart catheterization]] should be performed if screening is suggestive of the presence of PH.


==Screening==
==Screening==
Shown below is a table summarizing the recommended screening in several medical conditionas associated with elevated risk for PH.<ref>ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension</ref>
Shown below is a table summarizing the recommended screening in several medical conditionas associated with elevated risk for PH.<ref>ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension</ref><ref>ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension</ref>


{| style="cellpadding=0; cellspacing= 0; width: 600px;"
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 40%" align=center |'''Condition''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 60%" align=center |'''Recommended screening'''
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 40%" align="center" |'''Condition''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 60%" align="center" |'''Recommended screening'''
|-
|-
|style="font-size: 100; padding: 0 5px; background: #DCDCDC" align=left |''' Known [[BMPR2]] [[mutation]]''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align=left |[[Echocardiogram]] (yearly)
| style="font-size: 100; padding: 0 5px; background: #DCDCDC" align="left" |''' Known [[BMPR2]] [[mutation]]''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |[[Echocardiogram]] (yearly)
|-
|-
|style="font-size: 100; padding: 0 5px; background: #DCDCDC" align=left |'''BMPR2 [[mutation]] in a first degree relative''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align=left |[[Genetic counseling]] <br> [[BMPR2]] genotyping
| style="font-size: 100; padding: 0 5px; background: #DCDCDC" align="left" |'''BMPR2 [[mutation]] in a first degree relative''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |[[Genetic counseling]] <br> [[BMPR2]] genotyping
|-
|-
|style="font-size: 100; padding: 0 5px; background: #DCDCDC" align=left |'''Family history for PAH in 2 or more relatives'''||style="font-size: 100; padding: 0 5px; background: #F5F5F5" align=left | [[Genetic counseling]] <br> [[BMPR2]] genotyping
| style="font-size: 100; padding: 0 5px; background: #DCDCDC" align="left" |'''Family history for PAH in 2 or more relatives'''|| style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" | [[Genetic counseling]] <br> [[BMPR2]] genotyping
|-
|-
|style="font-size: 100; padding: 0 5px; background: #DCDCDC" align=left |'''[[Systemic sclerosis]]'''|| style="font-size: 100; padding: 0 5px; background: #F5F5F5" align=left |[[Echocardiogram]] (yearly)
| style="font-size: 100; padding: 0 5px; background: #DCDCDC" align="left" |'''[[Systemic sclerosis]]'''|| style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |[[Echocardiogram]] (yearly)
|-
|-
|style="font-size: 100; padding: 0 5px; background: #DCDCDC" align=left |'''[[Portal hypertension]]''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align=left |[[Echocardiogram]] if orthotopic liver transplantation is in consideration
| style="font-size: 100; padding: 0 5px; background: #DCDCDC" align="left" |'''[[Portal hypertension]]''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |[[Echocardiogram]] if orthotopic liver transplantation is in consideration
|-
|-
|style="font-size: 100; padding: 0 5px; background: #DCDCDC" align=left |'''[[Sickle cell disease]]''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align=left |[[Echocardiogram]] (yearly)
| style="font-size: 100; padding: 0 5px; background: #DCDCDC" align="left" |'''[[Sickle cell disease]]''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |[[Echocardiogram]] (yearly)
|-
|-
|style="font-size: 100; padding: 0 5px; background: #DCDCDC" align=left |'''Previous use of [[fenfluramine]]''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align=left |[[Echocardiogram]] in case of symptoms
| style="font-size: 100; padding: 0 5px; background: #DCDCDC" align="left" |'''Previous use of [[fenfluramine]]''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |[[Echocardiogram]] in case of symptoms
|-
|-
|style="font-size: 100; padding: 0 5px; background: #DCDCDC" align=left |'''[[Congenital heart disease]]''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align=left |[[Echocardiogram]] at the time of diagnosis
| style="font-size: 100; padding: 0 5px; background: #DCDCDC" align="left" |'''[[Congenital heart disease]]''' || style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" |[[Echocardiogram]] at the time of diagnosis
|}
|}


Revision as of 14:46, 27 March 2018

Pulmonary Hypertension Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pulmonary hypertension from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pulmonary hypertension screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Pulmonary hypertension screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pulmonary hypertension screening

CDC on Pulmonary hypertension screening

Pulmonary hypertension screening in the news

Blogs on Pulmonary hypertension screening

Directions to Hospitals Treating Pulmonary hypertension

Risk calculators and risk factors for Pulmonary hypertension screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assistant Editor(s)-in-Chief: Ralph Matar

Overview

Patients with a known BMPR2 mutation, scleroderma, and portal hypertension undergoing evaluation for liver transplantation should receive periodic screening for pulmonary hypertension (PH) through a thorough assessment of the presence of symptoms, physical examination, chest X ray, electrocardiography, and echocardiogram. Additional investigation with right heart catheterization should be performed if screening is suggestive of the presence of PH.

Screening

Shown below is a table summarizing the recommended screening in several medical conditionas associated with elevated risk for PH.[1][2]

Condition Recommended screening
Known BMPR2 mutation Echocardiogram (yearly)
BMPR2 mutation in a first degree relative Genetic counseling
BMPR2 genotyping
Family history for PAH in 2 or more relatives Genetic counseling
BMPR2 genotyping
Systemic sclerosis Echocardiogram (yearly)
Portal hypertension Echocardiogram if orthotopic liver transplantation is in consideration
Sickle cell disease Echocardiogram (yearly)
Previous use of fenfluramine Echocardiogram in case of symptoms
Congenital heart disease Echocardiogram at the time of diagnosis

Echocardiography findings that are suggestive of PH include:[3]

  1. Enlargement of the size of right atrium and right ventricle
  2. Decrease in the function of the right ventricle
  3. Displacement of the interventricular septum
  4. Tricuspid regurgitation
  5. Presence of pericardial effusion

References

  1. ↑ ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
  2. ↑ ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
  3. ↑ ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Pulmonary_hypertension_screening&oldid=1456812"